Tag: Takeda

Akeada, Biological E. Limited in partnership to hasten access to dengue vaccine
February 27, 2024 Off

Akeada, Biological E. Limited in partnership to hasten access to dengue vaccine

By Dino Mustafić

A strategic partnership between Akeada and Biological E. Limited aims to hasten access to QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs) for National Immunization Programs by 2030. MDVs offer cost and logistical benefits, with BE aiming for a manufacturing capacity of 50 million doses yearly to support Takeda’s goal of 100 million doses annually within the decade.

Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fibrotic Therapies in Inflammatory Bowel Disease
April 12, 2022 Off

Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fibrotic Therapies in Inflammatory Bowel Disease

By Author

Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, has entered into an agreement with Takeda to expand an existing collaboration to now include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.